Asset Details
Do you wish to reserve the book?
The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients
Do you wish to request the book?
The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The clinical signature of genetic variants and serum levels of macrophage migration inhibitory factor in Egyptian breast cancer patients
2024
Overview
Purpose
Macrophage migration inhibitory factor (MIF) is an integral cytokine for the modulation of both innate and adaptive immunity and is involved in the pathogenesis of various cancers. However, conflicting findings on the relationship between MIF polymorphisms and breast cancer (BC) have been reported in earlier research. We investigated the clinical value of serum MIF levels and the association between MIF rs1049829 and rs755622 variants with their serum levels and propensity to develop BC.
Methods
A total of 133 treatment-naïve Egyptian BC females and 126 apparently healthy controls were matriculated in this case–control study. The serum MIF protein levels were quantified by ELISA, whereas the genotyping was executed utilizing the TaqMan® allelic discrimination assay.
Results
A significant increase in the serum MIF level in BC cases was observed in comparison to control subjects (
P
< 0.0001), with a diagnostic potential to discriminate BC with 92.5% sensitivity and 73.7% specificity at a cut-off value > 9.47 ng/mL. Besides, a significant difference in serum MIF level was observed in BC cases with progesterone receptor (PR) negativity compared to those with PR positivity (
P
= 0.046). Moreover, a significant association was depicted between the rs1049829 variant of MIF gene and the protective effect against BC meanwhile the rs755622 variant demonstrated no significant link with BC risk.
Conclusions
This study revealed that serum MIF levels may be regarded as a promising serum tumor marker for BC. Also, the rs1049829 variant of the MIF gene is considered a protective candidate against BC.
Graphical Abstract
Publisher
Springer US,Springer,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Alleles
/ B cells
/ Biomarkers, Tumor - genetics
/ Cancer
/ Enzyme-linked immunosorbent assay
/ Ethylenediaminetetraacetic acid
/ Female
/ Females
/ Genetic Predisposition to Disease
/ Genotype
/ Humans
/ Intramolecular Oxidoreductases - blood
/ Intramolecular Oxidoreductases - genetics
/ Macrophage migration inhibitory factor
/ Macrophage Migration-Inhibitory Factors - blood
/ Macrophage Migration-Inhibitory Factors - genetics
/ Medicine
/ Oncology
/ Patients
/ Polymorphism, Single Nucleotide
/ Variants
/ Women
